|
|
| | EGFR-IN-109 Basic information |
| Product Name: | EGFR-IN-109 | | Synonyms: | EGFR-IN-109;[1]Benzothieno[2,3-d]pyrimidin-4(1H)-one, 2-(hydrazinylmethyl)-5,6,7,8-tetrahydro-7-methyl- | | CAS: | 3019971-97-9 | | MF: | C12H16N4OS | | MW: | 264.35 | | EINECS: | | | Product Categories: | | | Mol File: | 3019971-97-9.mol |  |
| | EGFR-IN-109 Chemical Properties |
| Boiling point | 537.9±60.0 °C(predicted) | | density | 1.63±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 5.51±0.10(predicted) |
| | EGFR-IN-109 Usage And Synthesis |
| Uses | EGFR-IN-109 (compound 4) is an EGFR inhibitor, with the IC50 values of 25.8 and 182.3nM for EGFRWT and EGFRT790M, respectively. EGFR-IN-109 arrests the cancer cells’ growth at the G2/M phase and induces both early and late apoptosis. EGFR-IN-109 can be used in cancer research[1]. | | IC 50 | EGFR: 25.8 nM (IC50); EGFRT790M: 182.3 nM (IC50); Caspase-3; Caspase-9; Bax; Bcl-2 | | References | [1] Sobh EA, et al. Computer aided drug discovery (CADD) of a thieno[2,3-d]pyrimidine derivative as a new EGFR inhibitor targeting the ribose pocket. J Biomol Struct Dyn. 2024 Mar;42(5):2369-2391. DOI:10.1080/07391102.2023.2204500 |
| | EGFR-IN-109 Preparation Products And Raw materials |
|